Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer

被引:2
作者
Guo, Yongkuan [1 ]
Zhang, Ran [1 ]
Meng, Yiran [2 ]
Wang, Li [2 ]
Zheng, Liuqing [2 ]
You, Jian [3 ]
机构
[1] Tianjin Canc Hosp, Airport Hosp, Natl Clin Res Ctr Canc, Dept Thorac Oncol, Tianjin, Peoples R China
[2] Hangzhou Repugene Technol Co Ltd, Hangzhou, Peoples R China
[3] Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Pulm Oncol,Canc Inst & Hosp, Tianjin, Peoples R China
关键词
ensartinib; EML4-ALK; osimertinib; resistance mechanism; case report; DABRAFENIB PLUS TRAMETINIB; ACQUIRED-RESISTANCE; OPEN-LABEL; EGFR; MECHANISMS; MUTATION; MULTICENTER; ALECTINIB; PATIENT; 1ST;
D O I
10.3389/fphar.2024.1359403
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Despite significant benefits from targeted therapy in patients with driver mutations, inevitable drug resistance usually occurred in non-small cell lung cancer, highlighting the necessity for sequential treatments to prolong overall survival. Unfortunately, durable drug response has not been reported in posterior-line therapy of cases with acquired EML4-ALK fusion after resistance to osimertinib, urging the need of referable decision-making in clinical management.Case presentation We present a case of a 71-year-old Chinese female, never smoker, diagnosed with invasive adenocarcinoma in the left inferior lobe of her lung, with metastases in regional lymph nodes. She received erlotinib treatment after the detection of coexistent EGFR L858R/G719S and BRAF V600E via next-generation sequencing of resected tumor tissue. Routine imaging revealed disease progression approximately 14 months after starting erlotinib treatment, followed by the detection of EGFR L858R through non-invasive liquid biopsy. Subsequently, osimertinib was administered, showing clinical activities for nearly 19 months until the emergence of an EML4-ALK fusion. Given the EML4-ALK fusion, a relatively rare resistance mechanism to osimertinib, she received third-line ensartinib treatment. One month later, alleviated tumor lesions plus normal serum marker levels demonstrated the effectiveness of ensartinib in overcoming resistance to osimertinib. Of note, the clinical response to ensartinib persisted for more than 14 months, superior to the previously reported efficacy of aletinib and crizotinib in osimertinib-failure cases. As of the last follow-up in July 2022, the patient showed no signs of recurrence and maintained a good life quality.Conclusion We reported a third-line ensartinib therapy in a patient with lung adenocarcinoma who developed an acquired EML4-ALK fusion after sequential treatment with erlotinib and osimertinib. Given the rarity of the EML4-ALK fusion as a resistance mechanism to osimertinib, ensartinib emerges as a promising treatment option for this specific clinical challenge, offering superior efficacy and good safety.
引用
收藏
页数:7
相关论文
共 42 条
  • [41] ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
    Zeng, Zhu
    Wang, Tao
    He, Junjun
    Wang, Yuehong
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
    Zhao, Yi
    Liu, Jingting
    Cai, Xiuyu
    Pan, Zhenkui
    Liu, Jun
    Yin, Weiqiang
    Chen, Hanzhang
    Xie, Zhanhong
    Liang, Hengrui
    Wang, Wei
    Guo, Zhihua
    Zhao, Shen
    Liang, Wenhua
    He, Jianxing
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2019, 367